INSIDER · CIK 1559583
Smither John W
Director at NewAmsterdam Pharma Co N.V. (NAMS) · Chief Financial Officer at MBX Biosciences, Inc. (MBX)
↗2 Form 4 rows in the window
Covers original filings from Aug 1, 2026 to Oct 29, 2026. Older trades and amendments are in the SEC history.
$0.00Bought on the market
$41KSold on the market
2Companies
Sep 9, 2026Latest filing
| Company | Title | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 202616:30 | Sep 4, 2026 | NAMSNewAmsterdam Pharma Co N.V. | Director | S · SellLate 5d | $25.32 | −1,600 | 8,760 | -15% | −$41K | ||
| Aug 4, 202608:51 | Aug 3, 2026 | MBXMBX Biosciences, Inc. | Chief Financial Officer | A · Grant | — | +28,000 | 28,000 | New | — |